JP2014501510A5 - - Google Patents

Download PDF

Info

Publication number
JP2014501510A5
JP2014501510A5 JP2013540387A JP2013540387A JP2014501510A5 JP 2014501510 A5 JP2014501510 A5 JP 2014501510A5 JP 2013540387 A JP2013540387 A JP 2013540387A JP 2013540387 A JP2013540387 A JP 2013540387A JP 2014501510 A5 JP2014501510 A5 JP 2014501510A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid residue
binding protein
terminal capping
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013540387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014501510A (ja
JP6173216B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/071084 external-priority patent/WO2012069655A2/en
Publication of JP2014501510A publication Critical patent/JP2014501510A/ja
Publication of JP2014501510A5 publication Critical patent/JP2014501510A5/ja
Application granted granted Critical
Publication of JP6173216B2 publication Critical patent/JP6173216B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013540387A 2010-11-26 2011-11-25 設計アンキリンリピートタンパク質のための改善されたキャッピングモジュール Active JP6173216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10192711.9 2010-11-26
EP10192711 2010-11-26
PCT/EP2011/071084 WO2012069655A2 (en) 2010-11-26 2011-11-25 Improved n-terminal capping modules for designed ankyrin repeat proteins

Publications (3)

Publication Number Publication Date
JP2014501510A JP2014501510A (ja) 2014-01-23
JP2014501510A5 true JP2014501510A5 (US20090208454A1-20090820-C00047.png) 2014-11-27
JP6173216B2 JP6173216B2 (ja) 2017-08-02

Family

ID=43858162

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013540386A Active JP6105479B2 (ja) 2010-11-26 2011-11-25 血清アルブミンに結合する設計リピートタンパク質
JP2013540387A Active JP6173216B2 (ja) 2010-11-26 2011-11-25 設計アンキリンリピートタンパク質のための改善されたキャッピングモジュール
JP2016211658A Pending JP2017048216A (ja) 2010-11-26 2016-10-28 血清アルブミンに結合する設計リピートタンパク質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013540386A Active JP6105479B2 (ja) 2010-11-26 2011-11-25 血清アルブミンに結合する設計リピートタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016211658A Pending JP2017048216A (ja) 2010-11-26 2016-10-28 血清アルブミンに結合する設計リピートタンパク質

Country Status (13)

Country Link
US (5) US9221892B2 (US20090208454A1-20090820-C00047.png)
EP (3) EP2643348A2 (US20090208454A1-20090820-C00047.png)
JP (3) JP6105479B2 (US20090208454A1-20090820-C00047.png)
KR (3) KR101782790B1 (US20090208454A1-20090820-C00047.png)
CN (3) CN103403024B (US20090208454A1-20090820-C00047.png)
AU (2) AU2011333666B2 (US20090208454A1-20090820-C00047.png)
BR (3) BR112013013043A2 (US20090208454A1-20090820-C00047.png)
CA (2) CA2818990C (US20090208454A1-20090820-C00047.png)
DK (1) DK2643349T3 (US20090208454A1-20090820-C00047.png)
ES (1) ES2758352T3 (US20090208454A1-20090820-C00047.png)
PL (1) PL2643349T3 (US20090208454A1-20090820-C00047.png)
RU (2) RU2636552C2 (US20090208454A1-20090820-C00047.png)
WO (2) WO2012069655A2 (US20090208454A1-20090820-C00047.png)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
KR101782790B1 (ko) * 2010-11-26 2017-09-28 몰리큘라 파트너스 아게 혈청 알부민에 결합하는 설계된 반복 단백질
PT2846836T (pt) 2012-05-07 2019-10-29 Allergan Inc Método de tratamento de dmi em doentes refratários à terapia anti-vegf
EP2867360B1 (en) * 2012-06-28 2019-05-08 Molecular Partners AG Designed ankyrin repeat proteins binding to platelet-derived growth factor
JP2015532306A (ja) * 2012-10-15 2015-11-09 チューリッヒ大学 癌治療のための二重特異性her2リガンド
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
EP3444278A1 (en) * 2013-02-26 2019-02-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
WO2016005969A1 (en) 2014-07-07 2016-01-14 Yeda Research And Development Co. Ltd. Method of computational protein design
MY179505A (en) 2015-04-02 2020-11-09 Molecular Partners Ag Recombinant binding proteins and their use
CA3036301C (en) * 2016-09-22 2021-04-20 Molecular Partners Ag Recombinant binding proteins comprising ankyrin repeat domains and their use
KR102634762B1 (ko) * 2016-11-01 2024-02-06 애로우헤드 파마슈티컬스 인코포레이티드 알파-v 베타-6 인테그린 리간드 및 그의 용도
WO2018165046A1 (en) 2017-03-07 2018-09-13 Igc Bio, Inc. A computational pipeline for antibody modeling and design
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
WO2019180243A1 (en) 2018-03-22 2019-09-26 Charité-Universitätsmedizin Berlin Crispr associated protein reactive t cell immunity
US20210253723A1 (en) 2018-06-15 2021-08-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
EP3864054A1 (en) 2018-10-08 2021-08-18 Universität Zürich Her2-binding tetrameric polypeptides
EP3883919A1 (en) 2018-11-21 2021-09-29 Universität Zürich Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction
EP3677911A3 (en) 2019-01-03 2020-07-29 Universität Basel Use of non-agonist ligands for suppression of metastasis
US20220088144A1 (en) 2019-01-11 2022-03-24 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
WO2020207771A1 (en) 2019-04-10 2020-10-15 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
BR112021024231A2 (pt) * 2019-06-04 2022-04-26 Molecular Partners Ag Proteínas de ligação fap recombinantes e uso da mesma
US20240124535A1 (en) 2019-06-04 2024-04-18 Molecular Partners Ag Designed ankyrin repeat domain with improved stability
KR20220016945A (ko) 2019-06-04 2022-02-10 몰리큘라 파트너스 아게 다중특이적 단백질
EP4025693A1 (en) 2019-09-05 2022-07-13 Genome Biologics UG Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure
WO2021116470A2 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins and their generation and use
CA3161326A1 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues
WO2021122813A1 (en) 2019-12-16 2021-06-24 Universität Basel Angiogenesis promoting agents for prevention of metastatic cancer
WO2021176008A1 (en) 2020-03-04 2021-09-10 Cornell University Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer
EP4132578A1 (en) 2020-04-06 2023-02-15 Universität Zürich Artc1 ligands for cancer treatment
WO2021224686A1 (en) 2020-05-06 2021-11-11 Molecular Partners Ag Novel ankyrin repeat binding proteins and their uses
WO2021229076A1 (en) * 2020-05-14 2021-11-18 Molecular Partners Ag Recombinant cd40 binding proteins and their use
TW202208408A (zh) 2020-05-14 2022-03-01 瑞士商分子夥伴股份有限公司 多特異性蛋白質
AU2021276332A1 (en) 2020-05-19 2022-11-17 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
WO2021239844A1 (en) 2020-05-27 2021-12-02 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes
WO2021239999A1 (en) 2020-05-28 2021-12-02 Universität Zürich Il-12 pd-l1 ligand fusion protein
KR20230048151A (ko) 2020-08-18 2023-04-10 유니버시타트 취리히 Cd25 편향된 항-il-2 항체
EP3957649A1 (en) * 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
US11981710B2 (en) * 2020-08-18 2024-05-14 Athebio Ag N-terminal capping modules of ankyrin repeat domains
CN114106194B (zh) * 2020-08-31 2024-01-16 中国科学院天津工业生物技术研究所 一种用于治疗糖尿病和/或肥胖症的融合蛋白
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
AU2021403658A1 (en) 2020-12-16 2023-06-29 Molecular Partners Ag Recombinant cd3 binding proteins and their use
AU2021403833A1 (en) 2020-12-16 2023-07-27 Molecular Partners Ag Novel slow-release prodrugs
WO2022171831A1 (en) 2021-02-11 2022-08-18 Universität Zürich Use of markers found on lymph node metastatic samples for the prognosis of breast cancer
EP4043481A1 (en) 2021-02-15 2022-08-17 Affilogic Compounds and methods for extending half life of biomolecules
US20240150475A1 (en) 2021-03-09 2024-05-09 Molecular Partners Ag Novel darpin based cd123 engagers
CA3211248A1 (en) 2021-03-09 2022-09-15 Nina RESCHKE Novel darpin based cd33 engagers
US20240156980A1 (en) 2021-03-09 2024-05-16 Molecular Partners Ag Protease cleavable prodrugs
AU2022234894A1 (en) 2021-03-09 2023-10-05 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
WO2022219185A1 (en) 2021-04-16 2022-10-20 Athebio Ag N-terminal capping modules of ankyrin repeat domains
IL310615A (en) 2021-08-05 2024-04-01 Immunos Therapeutics Ag Pharmaceutical compositions comprising HLA fusion proteins
KR20240045260A (ko) 2021-08-05 2024-04-05 이뮤노스 테라퓨틱스 아게 Hla 융합 단백질을 포함하는 복합 치료제
WO2023021006A1 (en) 2021-08-16 2023-02-23 Universität Zürich Il-1 targeting agents for treatment of pitiyriasis rubra pilaris
WO2023021050A1 (en) 2021-08-17 2023-02-23 Athebio Ag Variants of ankyrin repeat domains
EP4137508A1 (en) 2021-08-17 2023-02-22 Athebio AG Variants of ankyrin repeat domains
WO2023036849A1 (en) 2021-09-07 2023-03-16 ETH Zürich Identifying and predicting future coronavirus variants
EP4163380A1 (en) 2021-10-08 2023-04-12 ETH Zurich Device and method for manipulation of extracellular vesicles
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
EP4260907A1 (en) 2022-04-11 2023-10-18 Universität Zürich Agents for treatment of endometriosis and other benign gynecological neoplasms
WO2024002914A1 (en) 2022-06-27 2024-01-04 Charité-Universitätsmedizin Berlin Prediction of, and composition to improve, tendon healing
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024037743A1 (en) 2022-08-16 2024-02-22 Athebio Ag Variants of ankyrin repeat domains
WO2023194628A2 (en) 2022-08-16 2023-10-12 Athebio Ag Variants of ankyrin repeat domains
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ. 新規な結合タンパク質の生成と選択
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
ATE321849T1 (de) 1997-04-23 2006-04-15 Univ Zuerich Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
IL143238A0 (en) 1998-12-02 2002-04-21 Phylos Inc Dna-protein fusions and uses thereof
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
AU2002218166A1 (en) 2000-09-08 2002-03-22 Universitat Zurich Collections of repeat proteins comprising repeat modules
RU2299208C2 (ru) * 2001-05-08 2007-05-20 Шеринг Акциенгезельшафт Антраниламидпиридинамиды избирательного действия в качестве ингибиторов vegfr-2 и vegfr-3
JP2006512895A (ja) 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
ES2655912T3 (es) 2002-11-08 2018-02-22 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
EP2390268B1 (en) 2002-11-08 2017-11-01 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1732613A2 (en) 2004-04-06 2006-12-20 Affibody AB Use of serum albumin binding peptides conjugates for the preparation of a medicament
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
MX363423B (es) 2005-05-18 2019-03-22 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
DK1902131T3 (da) 2005-07-08 2010-03-01 Univ Zuerich Fag-display under anvendelse af cotranslational translokation af fusionspolypeptider
SI2402754T2 (sl) 2006-03-06 2023-09-29 Amunix Operating Inc. Nestrukturirani rekombinantni polimeri in njihove uporabe
WO2008028977A2 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2086998B1 (en) 2006-10-11 2011-12-07 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
EP2111228B1 (en) 2007-02-02 2011-07-20 Bristol-Myers Squibb Company 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis
DE602008005596D1 (de) 2007-06-21 2011-04-28 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
CN101765608B (zh) 2007-07-31 2015-03-11 阿菲博迪公司 新白蛋白结合组合物、方法及应用
EP2198022B1 (en) 2007-09-24 2024-03-06 University Of Zurich Designed armadillo repeat proteins
EP2263088A2 (en) * 2008-03-19 2010-12-22 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
EP2358746B1 (en) 2008-11-03 2020-09-16 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
US9154968B2 (en) * 2010-11-03 2015-10-06 Telefonaktiebolaget L M Ericsson (Publ) Radio base station and a method therein
KR101782790B1 (ko) * 2010-11-26 2017-09-28 몰리큘라 파트너스 아게 혈청 알부민에 결합하는 설계된 반복 단백질
EA201391607A1 (ru) 2011-04-29 2014-04-30 Янссен Байотек, Инк. Связывающие il4/il13 белки с повторами и их применение
EP2867360B1 (en) 2012-06-28 2019-05-08 Molecular Partners AG Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2738180A1 (en) * 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
MY179505A (en) * 2015-04-02 2020-11-09 Molecular Partners Ag Recombinant binding proteins and their use

Similar Documents

Publication Publication Date Title
JP2014501510A5 (US20090208454A1-20090820-C00047.png)
RU2013128895A (ru) Улучшенные n-терминальные кэппинг модули для сконструированных белков с анкириновым повтором
JP2013172734A5 (US20090208454A1-20090820-C00047.png)
NZ593833A (en) Extended recombinant polypeptides and compositions comprising same
HRP20192314T1 (hr) Pripravci faktora viii i postupci pripreme i njihove uporabe
JP2010065037A5 (US20090208454A1-20090820-C00047.png)
JP2014193892A5 (US20090208454A1-20090820-C00047.png)
JP2015212284A5 (US20090208454A1-20090820-C00047.png)
JP2017048194A5 (US20090208454A1-20090820-C00047.png)
JP2010534684A5 (US20090208454A1-20090820-C00047.png)
JP2014224126A5 (US20090208454A1-20090820-C00047.png)
EP3670536A3 (en) Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
JP2013507132A5 (US20090208454A1-20090820-C00047.png)
RU2016146198A (ru) Терапевтические dll4-связывающие белки
JP2015525217A5 (US20090208454A1-20090820-C00047.png)
JP2010519252A5 (US20090208454A1-20090820-C00047.png)
JP2016500250A5 (US20090208454A1-20090820-C00047.png)
JP2013048638A5 (US20090208454A1-20090820-C00047.png)
JP2011521902A5 (US20090208454A1-20090820-C00047.png)
JP2010166916A5 (US20090208454A1-20090820-C00047.png)
JP2009529509A5 (US20090208454A1-20090820-C00047.png)
JP2009527226A5 (US20090208454A1-20090820-C00047.png)
JP2005120106A5 (US20090208454A1-20090820-C00047.png)
JP2010088434A5 (US20090208454A1-20090820-C00047.png)
JP2012115277A5 (US20090208454A1-20090820-C00047.png)